Finland· FI-REL-REL1895
Naprosyn
A naproxen product, registered in Finland by Roche Oy. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Naproxen is registered in 15 of 19 countries.
Countries holding a registration under ATC M01AE02 (naproxen), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Naproxen · ATC M01AE02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of naproxen costs, country by country.
Normalised to the WHO defined daily dose (0.5 g), the median price runs from $0.16 in Italy to $0.82 in Switzerland — a ×4.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Naproxen · price per daily dose (0.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$0.82
- IT Italy$0.16
The record
At a glance
Fimea (Finland)- Manufacturer
- Roche Oy
- Country
- Finland (FI)
- ATC code
- M01AE02
- ATC class
- Naproxen
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
495 interactions on record for naproxen.
Graded by severity as the source publishes them — 58 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Naproxen · interactions on record
495 records
- 58 severe
- 176 moderate
- 17 minor
- 161 info
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
83 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M01AE02
Naproxen, as other registers publish it.
- United States24/7 Life by 7-Eleven Naproxen SodiumLil' Drug Store Products, Inc.
- United StatesAleveBayer HealthCare LLC.
- FinlandAleveBayer Oy
- PolandAleveInPharm Sp. z o.o.
- United StatesAleveLil' Drug Store Products, Inc
- United StatesAleveNavajo Manufacturing Company Inc.
- PolandAleveDelfarma Sp. z o.o.
- PolandAleveBayer Sp. z o.o.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b04d9396-b710-483f-9273-662d1275b3bb GET /v1/drugs/b04d9396-b710-483f-9273-662d1275b3bb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.5",
"form": "oraalisuspensio",
"route": null,
"ddd_unit": "g",
"strength": "25 mg/ml",
"atc_label": "naprokseeni",
"ma_number": "9112",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL1895",
"authorised_at": "1985-09-18"
}See everything about naproxen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.